Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials

A Amstutz, B Speich, F Mentré, CS Rueegg… - The Lancet …, 2023‏ - thelancet.com
Background Interpretation of the evidence from randomised controlled trials (RCTs) of
remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European …

H Ludwig, E Terpos, N van de Donk, MV Mateos… - The Lancet …, 2023‏ - thelancet.com
T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …

Enhanced evasion of neutralizing antibody response by Omicron XBB. 1.5, CH. 1.1, and CA. 3.1 variants

P Qu, JN Faraone, JP Evans, YM Zheng, C Carlin… - Cell reports, 2023‏ - cell.com
Omicron subvariants continuingly challenge current vaccination strategies. Here, we
demonstrate nearly complete escape of the XBB. 1.5, CH. 1.1, and CA. 3.1 variants from …

[HTML][HTML] Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA. 2.86 and FLip variants

P Qu, K Xu, JN Faraone, N Goodarzi, YM Zheng… - Cell, 2024‏ - cell.com
Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we
characterized BA. 2.86 and XBB-derived variant FLip by investigating their neutralization …

Deep-learning-enabled protein–protein interaction analysis for prediction of SARS-CoV-2 infectivity and variant evolution

G Wang, X Liu, K Wang, Y Gao, G Li… - Nature Medicine, 2023‏ - nature.com
Host–pathogen interactions and pathogen evolution are underpinned by protein–protein
interactions between viral and host proteins. An understanding of how viral variants affect …

A living WHO guideline on drugs for covid-19

A Agarwal, BJ Hunt, M Stegemann, B Rochwerg… - bmj, 2020‏ - bmj.com
Updates This is the fourteenth version (thirteenth update) of the living guideline, replacing
earlier versions (available as data supplements). New recommendations will be published …

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG. 5.1 and XBB. 2.3

JN Faraone, P Qu, N Goodarzi, YM Zheng… - Emerging Microbes & …, 2023‏ - Taylor & Francis
Immune evasion by SARS-CoV-2 paired with immune imprinting from monovalent mRNA
vaccines has resulted in attenuated neutralizing antibody responses against Omicron …

Antiviral and bivalent vaccine efficacy against an omicron XBB. 1.5 isolate

R Uraki, M Ito, M Kiso, S Yamayoshi… - The Lancet Infectious …, 2023‏ - thelancet.com
As of January 2023, SARS-CoV-2 subvariants BQ. 1 (a BA. 5 subvariant) and XBB (a BA. 2
subvariant) have replaced previously dominant omicro n variants globally, including BA. 5 …

Clinical course and management of COVID-19 in the era of widespread population immunity

EA Meyerowitz, J Scott, A Richterman, V Male… - Nature Reviews …, 2024‏ - nature.com
The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB. 1.5 and BQ. 1.1 subvariants

D Ao, X He, W Hong, X Wei - MedComm, 2023‏ - Wiley Online Library
As the fifth variant of concern of the SARS‐CoV‐2 virus, the Omicron variant (B. 1.1. 529)
has quickly become the dominant type among the previous circulating variants worldwide …